Claims for Patent: 4,944,942

Summary for Patent: 4,944,942

Title:	Intranasal vaccination of horses with inactivated microorganisms or antigenic material
Abstract:	Horses can be immunized by the intranasal administration of antigenic material which provokes the proliferation of antibodies which reduce or neutralize the virulence of invasive microorganisms. These antigenic materials may be inactivated whole organisms, extracts from such organisms, or recombinant DNA or synthetic peptide antigens. This antigenic material can be combined with adjuvants and transdermal carriers or it can just be carried in sterile water. The intranasal vaccination may be part of a total regimen that includes other routes of administration such as intramuscular injection.
Inventor(s):	Brown; Karen K. (Kansas City, MO), Bryant; Sharon A. (Shawnee, KS)
Assignee:	Mobay Corporation (Pittsburgh, PA)
Application Number:	07/090,272
Patent Claims:	1. A process of immunizing horses against infection by Streptococcus equi comprising applying inactivated organisms, antigenic extracts, or recombinant DNA or synthetic peptide antigens of Streptococcus equi to the nasal mucosa or tonsilor tissue of said horses in a dose sufficient to increase the negative log of LD.sub.50. 2. The process of claim 1 wherein the antigenic material is incorporated into a liquid carrier and sprayed onto the walls of the nose in the vicinity of the tonsilor tissue as a liquid stream or large droplets. 3. The process of claim 2 wherein the liquid carrier also contains a transdermal penetrant. 4. The process of claim 3 wherein the transdermal penetrant is either dimethyl sulfoxide or methyl salicylate. 5. The process of claim 2 wherein the liquid carrier also contains a thickening agent. 6. The process of claim 5 wherein the thickening agent is cellulose based. 7. The process of claim 6 wherein the thickening agent is hydroxyethylcellulose. 8. The process of claim 5 wherein the liquid carrier also contains a transdermal penetrant. 9. The process of claim 8 wherein (a) the liquid carrier is water, and (b) the thickening agent is cellulose based. 10. The process of claim 9 wherein (a) the transdermal penetrant is dimethyl sulfoxide or methyl salicylate, and (b) the thickening agent is hydroxyethylcellulose. 11. The process of claim 1 in which the antigenic material is an enzyme extract of Streptococcus equi. 12. A process of immunizing horses against respiratory infection by Streptococcus equi comprising (a) an intramuscular injection of said horses with a vaccine based on killed organisms, antigenic extracts or recombinant DNA or synthetic peptide antigens of Streptococcus equi, and (b) an intranasal application of said horses with a vaccine based on killed organisms, antigenic extracts or recombinant DNA or synthetic peptide antigens of Streptococcus equi in a dose sufficient to increase the negative log of LD.sub.50. 13. The process of claim 12 wherein the intranasally applied vaccine includes a liquid carrier and is sprayed onto the walls of the horse's nose in the vicinity of the tonsilor tissue as a liquid stream or large droplets. 14. The process of claim 13 wherein the liquid carrier is sterile water and the injected vaccine contains an adjuvant. 15. The process of claim 14 wherein the intranasal vaccine is free of adjuvant. 16. The process of claim 12 wherein (a) the injected vaccine contains an adjuvant, (b) the intranasal vaccine carrier comprises water and is sprayed onto the walls of the horse's nose in the vicinity of the tonsilor tissue as a liquid stream or large droplets, and (c) the antigenic material in both vaccines is an enzyme extract. 17. A process of immunizing horses against the respiratory invasion of Streptococcus equi comprising (a) preparing a waterborne antigenic enzyme and detergent extract of Streptococcus equi which displays a combining power value of at least about four in the mouse combining power test, (b) adding between about 0.25 and 1 weight % of hydroxyethylcellulose and between about 2.5 and 10 weight % of dimethyl sulfoxide, based on the total formulation, to the waterborne extract, (c) applying between about 1 and 3 milliliters of this formulation to the nasal tonsilor tissue of the horse by spraying it as a liquid stream or large droplets on the interior nasal wall in the vicinity of this tissue in a dose sufficient to increase the negative log of LD.sub.50, and (d) repeating the application in between about one (1) and four (4) weeks of the initial application. 18. The process of claim 17 wherein the formulation is applied by inserting a small diameter tube sealed at its distal end and with circumferential holes near this end into the horse's nose in the vicinity of the tonsilor tissue and passing the formulation through this tube. 19. The process of claim 17 wherein the horse's head is tilted back, and the tube is inserted in no farther than the beginning of the tonsilor tissue so that the applied formulation can flow along the nasal wall under the influence of gravity to this tissue.

Details for Patent 4,944,942

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23